We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients

This study has been terminated.
(Unable to recruit eligible subjects; no data analyzed)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01002118
First Posted: October 27, 2009
Last Update Posted: August 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Jennifer G. Robinson, University of Iowa
  Purpose
Cardiovascular disease and mortality is the largest comorbidity within the dialysis population. Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent United States Renal Data System (USRDS), 40% of incident dialysis patients will have a cardiovascular event or die within the first 9 months of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3 fatty acid doses on cardiovascular parameters in an incident hemodialysis population. Initially, this will be a pilot study. Ultimately, the information will be used to adequately plan for a larger intervention trial using Omega-3 fatty acids in incident hemodialysis patients.

Condition Intervention
Cardiovascular Disease Drug: Omega-3 Acid Ethyl Esters Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients

Resource links provided by NLM:


Further study details as provided by Jennifer G. Robinson, University of Iowa:

Primary Outcome Measures:
  • Determine Recruitment Rates [ Time Frame: 4 months ]
    Determine recruitment by number eligible/number enrolled


Secondary Outcome Measures:
  • Assess the Effectiveness of Omega-3 Fatty Acid Compared to Placebo on Electrocardiographic Parameters. [ Time Frame: 4 months ]
    percent of subjects with significant arrhythmia present on Holter electrocardiography

  • Medication Adherence [ Time Frame: 4 months ]
    percent of pills taken each month calculated as number of pills taken/number of pills dispensed


Enrollment: 1
Actual Study Start Date: January 25, 2008
Study Completion Date: February 23, 2011
Primary Completion Date: February 23, 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
4 capsules inert oil Placebo each day for 16 weeks
Drug: Placebo
4 capsules each day for 16 weeks
Active Comparator: Omega-3 Fatty Acid Ethyl Esters
4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
Drug: Omega-3 Acid Ethyl Esters
1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
Other Name: Lovaza Omega-3 Acid Ethyl Esters 4g capsule

Detailed Description:

Cardiovascular disease and mortality is the largest comorbidity within the dialysis population.

Nearly 50% of hemodialysis patients will have congestive heart failure at initiation. According to the most recent USRDS data, 40% of incident dialysis patients will have a cardiovascular event or die within the first 9 months of dialysis. The risk of sudden cardiac death is estimated to be 6.9% per year of dialysis. Despite this, a recent study found that only 8% of dialysis patients received an implantable defibrillator. Numerous studies have looked at the acute cardiac effects of hemodialysis. Changes in the QT interval, elevations in troponins, increased heart rate variability and heart have all been noted. The mechanisms behind these changes and potential preventative measures remain unknown. It has been postulated that Omega-3 fatty acids could provide beneficial cardioprotection in hemodialysis patients. In nonhemodialysis populations, omega-3 fatty acids (FA) have established anti-arrhythmic properties and have been shown to reduce the risk of sudden death and to reduce cardiac mortality. In a study of hemodialysis patients, a high dose of omega-3 FA (5 grams daily) had beneficial effects on electrocardiographic (ECG) surrogate markers of sudden death, such as heart rate, heart rate variability, and baroreflex sensitivity. One small 2-year study of 1.7 grams omega-3 FA in 206 hemodialysis subjects showed a significant reduction in myocardial infarction but was not large enough to detect an effect on cardiac or total mortality. While these studies are suggestive, the potential therapeutic benefit remains unclear and the appropriate dose of Omega-3 in dialysis patients to achieve benefit is unknown. Doses of Omega-3 that have shown electrocardiogram benefits were high and require 6-8 capsules daily. Long-term adherence is likely to be suboptimal with this high pill burden. Studies with smaller doses have been of insufficient size to determine any cardiovascular benefit. We propose to evaluate two Omega-3 fatty acid doses on cardiovascular parameters in a hemodialysis population. Initially, this will be a pilot study. Ultimately, the information will be used to adequately plan for a larger intervention trial using Omega-3 fatty acids in incident hemodialysis patients. I.5 Specify your research question(s), study aims or hypotheses (do not indicate "see protocol") Specific aim 1. Determine recruitment and medication adherence rates Recruitment will take place over 6 months and include incident hemodialysis patients with a 4 month follow-up. Total expected time for the pilot is one year. Participants will be randomized to either moderate dose Omega-3 (4 grams), or 4 tables of placebo. Rates of participation, medication adherence and drop out rates will be used to plan future trials. HawkIRB https://hawkirb.research.uiowa.edu/hawkirb/summary/projects.page?mode=pf&OID=5961841[1/27/2010 2:46:08 PM] Specific aim 2. Assess the effectiveness of two Omega-3 fatty acid doses compared to placebo on electrocardiographic parameters. All participants will have a cardiovascular evaluation at baseline and at end of study. This will include a 48-hour Holter monitor, vital signs and blood studies of various cardiovascular risk markers. Specifically, we will be assessing heart rate variability, heart rate and QT dispersion.

Specific aim 3. Assess the side effect profiles of 3.4 g Omega-3 fatty acids to placebo.

The success of future trials will require subject compliance with therapy. By evaluating the side effects of Omega-3, we will be better able to determine the tolerability for future studies.

I Selection of study endpoints. Since this is a feasibility study there will be insufficient power to detect changes in physiologic parameters. Omega-3 FA have been shown to beneficially influence autonomic function parameters measured by 48-hour Holter we have selected as our secondary endpoints changes HRV, heart rate, and QT duration for a dose-ranging study. Blood samples will be obtained and properly stored for future studies.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 years old
  • Initiated dialysis in past 3 months
  • Signed informed consent
  • Attending University of Iowa dialysis unit for duration of the study

Exclusion Criteria:

  • Age >70
  • Unable to provide consent
  • Currently taking fish oil supplementation
  • rhythm other than sinus
  • implantable cardioverter-defibrillator
  • pacemaker
  • myocardial infarction,revascularization or unstable angina in past 3 months
  • other hospitalization in past 3 months
  • symptomatic heart failure
  • known left ventricular ejection fraction < 30%
  • history of a significant bleeding disorder
  • severe bleeding episode requiring hospitalization in past 3 months (GI bleed or hemorrhagic stroke)
  • unexplained HgB drop > 2 gm/dl in past 3 months
  • chronic warfarin or anti-coagulation therapy (such as Lovenox)
  • pregnant or nursing mothers
  • allergic to fish, fish oil or fish products
  • Participation in other trials of investigational products
  • other characteristics as determined by the investigator that would make sudy participation inappropriate
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002118


Locations
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
GlaxoSmithKline
Investigators
Principal Investigator: Jennifer Robinson, MD MPH University of Iowa
  More Information

Responsible Party: Jennifer G. Robinson, Principal Investigator, University of Iowa
ClinicalTrials.gov Identifier: NCT01002118     History of Changes
Other Study ID Numbers: 200801761
First Submitted: October 23, 2009
First Posted: October 27, 2009
Results First Submitted: May 2, 2017
Results First Posted: August 9, 2017
Last Update Posted: August 9, 2017
Last Verified: August 2017

Keywords provided by Jennifer G. Robinson, University of Iowa:
heart rate variability
Dialysis

Additional relevant MeSH terms:
Cardiovascular Diseases